Dashboard
Manage Tickers

QGEN QIAGEN N.V.

NYSE qiagen.com


$ 48.27 $ 0.14 (0.29 %)    

Friday, 17-Oct-2025 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 48.27
$ 48.04
$ 42.85 x 1
$ 55.00 x 88
$ 47.97 - $ 48.46
$ 37.43 - $ 51.88
704,985
na
10.73B
$ 0.76
$ 128.36
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

reported-earlier-qualigen-therapeutics-launches-cxc10-asset-purchases-after-market-shakeout-emphasizing-smart-investment-framework-and-risk-management
Reported Earlier, Qualigen Therapeutics La...
10/13/2025 06:22:26

qiagen-obtains-ce-ivdr-certification-for-its-full-portfolio-of-qiastat-dx-syndromic-testing-systems-and-panels
Qiagen Obtains CE-IVDR Certification For I...
09/10/2025 20:07:52

Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to hig...

qiagen-expands-qiastat-dx-portfolio-in-us-with-fda-clearance-of-rise-for-rapid-infectious-disease-diagnostics
QIAGEN Expands QIAstat-Dx Portfolio In US ...
09/02/2025 06:18:28

U.S. market entry set to begin for QIAstat-Dx Rise – a version of QIAstat-Dx for syndromic testing that combines unparalleled t...

doordash-to-rally-around-30-here-are-10-top-analyst-forecasts-for-thursday
DoorDash To Rally Around 30%? Here Are 10 ...
08/07/2025 17:24:25

ubs-maintains-neutral-on-qiagen-raises-price-target-to-50
UBS Maintains Neutral on Qiagen, Raises Pr...
08/07/2025 16:54:00

UBS analyst John Sourbeer maintains Qiagen (NYSE:QGEN) with a Neutral and raises the price target from $48 to $50.

qiagen-q3--expected-to-be-more-than-058-vs-058-est-q3--revenue-expected-to-be-more-than-522080m-vs-516216m-est
Qiagen Q3 expected to be more than $0.58 ...
08/05/2025 20:12:02

Qiagen (NYSE:QGEN) Q3 expected to be more than $0.58 vs $0.58 Est. Q3 Revenue expected to be more than $522.080M vs $516.216M...

qiagen-sees-fy2025-adj-eps-235-vs-235-est-sees-sales-2057b-2077b-vs-2063b-est
Qiagen Sees FY2025 Adj EPS $2.35 vs $2.35 ...
08/05/2025 20:10:40

Qiagen (NYSE:QGEN) is looking for FY2025 Adj EPS of $2.35 vs $2.35 analyst estimate. sees sales of $2.057 billion-$2.077 billio...

qiagen-q2-adj-eps-060-inline-sales-534000m-beat-523699m-estimate
Qiagen Q2 Adj. EPS $0.60, Inline, Sales $5...
08/05/2025 20:06:08

Qiagen (NYSE:QGEN) reported quarterly earnings of $0.60 per share which met the analyst consensus estimate. This is a 5.26 perc...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

a-look-at-qiagens-upcoming-earnings-report
A Look at Qiagen's Upcoming Earnings Report
08/04/2025 15:02:15

Core News & Articles
QIAGEN Launches QIAseq xHYB Long Read Pane...
07/22/2025 20:09:09

Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read s...

b-of-a-securities-maintains-buy-on-qiagen-raises-price-target-to-53
B of A Securities Maintains Buy on Qiagen,...
06/26/2025 17:55:49

B of A Securities analyst Derik De Bruin maintains Qiagen (NYSE:QGEN) with a Buy and raises the price target from $50 to $53.

qiagen-elects-stephen-rusckowski-as-chairman-of-supervisory-board-shareholders-approve-annual-cash-dividend-of-025shr-and-synthetic-share-repurchase-authorization-of-up-to-500m
QIAGEN Elects Stephen Rusckowski As Chairm...
06/26/2025 17:22:41

Stephen H. Rusckowski elected as Chairman of the Supervisory Board after AGM; former Chairman Lawrence A. Rosen did not stand f...

barclays-initiates-coverage-on-qiagen-with-overweight-rating-announces-price-target-of-55
Barclays Initiates Coverage On Qiagen with...
06/24/2025 13:17:58

Barclays analyst Luke Sergott initiates coverage on Qiagen (NYSE:QGEN) with a Overweight rating and announces Price Target o...

qiagen-and-gencurix-partners-to-develop-oncology-assays-for-use-on-qiacuitydx-platform-digital-pcr-system-designed-for-clinical-diagnostics
QIAGEN And GENCURIX Partners To Develop On...
06/18/2025 20:06:30

GENCURIX partnership marks launch of new QIAcuityDx Partnering Program for third-party in vitro diagnostic (IVD) assay developm...

Core News & Articles
Reported Sunday, Incyte Taps QIAGEN And Il...
06/16/2025 07:57:11

QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene al...

reported-earlier-tracer-biotechnologies-and-qiagen-partner-to-co-develop-blood-based-mrd-assays-for-solid-tumors-on-qiacuity-digital-pcr-platform
Reported Earlier, Tracer Biotechnologies A...
06/06/2025 06:57:06

This collaboration aims to deliver highly sensitive, cost-effective, and decentralized MRD testing solutions that enable oncolo...

qiagen-expands-oncology-diagnostics-portfolio-with-two-strategic-partnerships-to-advance-use-of-mrd-testing-in-clinical-trials-to-support-pharma-co-development-projects-for-companion-diagnostics
QIAGEN Expands Oncology Diagnostics Portfo...
06/02/2025 18:07:32

Two new partnerships enhance QIAGEN's capabilities to support pharma partner clinical trials with significant expansion of ...

foresight-diagnostics-partners-with-qiagen-to-develop-commercialize-kit-based-version-of-clarity-assay-for-lymphoma
Foresight Diagnostics Partners With QIAGEN...
06/02/2025 17:02:13

Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, ...

qiagen-announces-new-commercial-partnership-and-co-marketing-agreement-with-id-solutions-to-expand-availability-of-dpcr-assays-for-oncology-research-applications
QIAGEN Announces New Commercial Partnershi...
05/22/2025 20:31:07

Partnership designed to expand QIAGEN's leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platfo...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION